Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Thursday that its fourth quarter revenues rose 64 percent year over year, thanks to a 66 percent increase in the number of completed Cologuard colorectal cancer tests during the quarter.

For the three months ended Dec. 31, 2018, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $143.0 million for Q4, up from $87.4 million in Q4 2017, and beating the average Wall Street estimate of $134.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan is to release rules governing some gene-edited food, according to NHK World.

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.